Resource library

The purpose of this guide is to provide information for health service organisations to help them improve the quality of care and health outcomes for Aboriginal and Torres Strait Islander people based on the National Safety and Quality Health Service Standards.

These guidelines are intended for those developing, assessing, procuring and implementing IT systems for medication management and electronic prescribing to:

• Understand how design contributes to patient safety
• Apply the recommendations during software development and iteration
• Evaluate systems during procurement

This guidance outlines strategies and principles developed to address safe selection and storage of all medicines, including look-alike, sound-alike (LASA) medicines.

The purpose of this advisory is to clarify the applicability of the Aboriginal and Torres Strait Islander specific actions in the National Safety and Quality Health Service Standards.

The purpose of this guide is to provide clinicians with evidence-based strategies to support them to understand and fulfil their roles and responsibilities. It combines information from a range of existing guides and resources, including the National Safety and Quality Health Service Standards User Guide for Medication Management in Cancer Care.

Delivering comprehensive care is delivered when conditions support the healthcare workforce to provide person-centred value-based care.

This User Guide describes best practice strategies under each of the 28 specific actions to support organisations to deliver effective medication management in cancer services.

This survey tool provides Australian health service organisations with a set of 14 principles supported by a variety of risk reduction strategies. The tool should be used in conjunction with the Principles for the safe selection and storage of medicines – Guidance and survey tool.

The Commission has revised the National Tall Man Lettering List to include cloBAZam in the benzodiazepine class of medicines, based on the reporting of adverse events and near misses and its high similarity and likelihood of confusion with another benzodiazepine: CLONAZepam.